A large supply of the anti-anemia drug, known as Rubramin B12, has been contributed to Hadassah by E.R. Squibb and Co, for immediate shipment to the network of hospitals maintained in Israel by Hadassah, it was announced today by Mrs. Rebecca Shulman, chairman of the organization’s Medical Organization Committee.
The new drug, which is administered intramuscularly, has achieved extraordinary results and had been requested by Hadassah medical staffs in Israel. E.R. Squibb and Co. contributed approximately 20,000 vials of the new drug, which Mrs. Shulman said was most needed to take care of the many pernicious anemia patients in Hadassah hospitals and in the Hadassah Public Health Community Center at Bet Mazmil, near Jerusalem.
JTA has documented Jewish history in real-time for over a century. Keep our journalism strong by joining us in supporting independent, award-winning reporting.
The Archive of the Jewish Telegraphic Agency includes articles published from 1923 to 2008. Archive stories reflect the journalistic standards and practices of the time they were published.
